The Future of Dermatology Regulation

The implementation of the Elsa artificial intelligence system at the Food and Drug Administration represents a pivotal yet contentious moment in the history of federal drug regulation. As reported by CNN on July 23, 2025, the rollout of this internal generative AI tool, championed by FDA Commissioner Marty Makary, was designed to revolutionize the way the agency handles the massive influx of clinical data, adverse event reports, and pharmaceutical applications. However, the early stages of this integration have been marred by significant technical failures and systemic concerns regarding the accuracy of regulatory decisions. The following summary examines the rise of Elsa, the internal friction it has caused within the FDA, and the specific, far-reaching implications this technology holds for the field of clinical dermatology.

The Vision and Implementation of Elsa

The Elsa project was born from a desire to modernize an agency often criticized for its bureaucratic pace. Named after a late FDA staffer, the tool was built using Anthropic’s Claude model and hosted within a secure government cloud environment to ensure data privacy. The primary objective was to automate the most labor-intensive aspects of a reviewer’s job: summarizing thousands of pages of clinical trial data, comparing complex drug labels, and synthesizing safety signals from post-market surveillance. Commissioner Makary argued that by reducing tasks that previously took days or weeks down to mere minutes, the agency could alleviate the “busywork” that plagues its professional staff. This efficiency was framed not just as a convenience, but as a moral imperative to bring life-saving medications to patients faster, particularly those suffering from rare or terminal conditions.

The Crisis of AI Hallucinations and Accuracy

Despite the optimistic projections from leadership, the practical application of Elsa has revealed a disturbing trend of “hallucinations,” a phenomenon where generative AI produces confident but entirely fabricated information. Internal reports and interviews with agency staff indicate that Elsa has frequently invented citations, referenced non-existent clinical studies, and mischaracterized data points within drug applications. This has created a paradoxical situation where the tool, intended to save time, has actually increased the workload for many reviewers. Staff members report having to spend extra hours cross-referencing every claim made by the AI against original source documents to ensure that no fraudulent or erroneous data enters the official regulatory record. The risk is not merely administrative; if a fake study or a fabricated safety profile is used to justify a drug’s approval, the consequences for public health could be catastrophic.

Internal Resistance and the Workforce Mandate

The aggressive push to integrate Elsa has also been linked to broader political and structural changes within the federal government. In early 2025, mandates to significantly reduce the federal workforce placed immense pressure on agency heads to find technological replacements for human labor. Critics within the FDA argue that the “turbo-charged” rollout of Elsa is less about improving scientific review and more about justifying staff cuts. There is a growing concern that as the workforce shrinks, the remaining reviewers will be under such extreme time pressure that they may stop double-checking the AI’s work. This environment creates a dangerous vulnerability where the agency’s “gold standard” of review could be compromised by a reliance on automated summaries that lack the nuance and skepticism of a human scientist.

Strategic Impact on Dermatological Innovation

For the field of dermatology, the Elsa controversy is particularly relevant because of the high volume of new biologics and topical therapies currently in the pipeline. Dermatology has seen an explosion of innovation in recent years, particularly for conditions like atopic dermatitis, psoriasis, and alopecia areata. The promise of Elsa is that it could drastically shorten the “drug lag” for these therapies. If the AI can accurately synthesize the complex immunological data associated with new Janus kinase inhibitors or monoclonal antibodies, patients could gain access to life-changing treatments months earlier than under the traditional manual review process. The speed of Elsa could be a major boon for dermatologists who manage chronic, debilitating skin diseases that require a constant influx of new therapeutic options.

Challenges for AI Integration in Skin Cancer Diagnostics

Beyond pharmaceutical approvals, the FDA’s internal struggles with Elsa reflect the external challenges of regulating AI-enabled medical devices, which are more prevalent in dermatology than in almost any other specialty. Dermatologists increasingly rely on AI tools for skin cancer screening and lesion analysis. The fact that the FDA’s own internal AI is prone to making up data raises serious questions about how the agency will validate the algorithms submitted by private companies. If the regulator cannot trust its own internal AI to summarize a paper accurately, the scrutiny applied to diagnostic skin cancer apps will likely intensify. This could lead to more rigorous clinical trial requirements for dermatology tech companies, as the agency may become increasingly wary of the “black box” nature of machine learning.

Safety Surveillance and the Future of Patient Care

The most immediate benefit—and risk—for dermatology lies in post-market safety surveillance. Skin medications often reveal rare side effects only after they are used by millions of people in the real world. Elsa’s ability to scan thousands of adverse event reports could allow the FDA to identify safety signals, such as rare skin reactions or systemic complications, much faster than humanly possible. However, if the AI “hallucinates” or misses a subtle pattern in the data, a dangerous side effect could go unnoticed for months. For the practicing dermatologist, the reliability of the FDA’s AI directly impacts the safety of the prescriptions they write every day. The evolution of Elsa will ultimately determine whether the next generation of skin treatments is defined by rapid, data-driven breakthroughs or by a decline in regulatory rigor.

Source:https://www.cnn.com/2025/07/23/politics/fda-ai-elsa-drug-regulation-makary